Cybin Reports FY Net Loss of $148 Million, Up from $81.6 Million Last Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
Source: seekingalpha
- Deteriorating Financials: Cybin's FY report reveals a net loss of $148 million, up from $81.6 million last year, indicating increased pressure from R&D and operational costs, which may hinder future financing capabilities.
- Cautious Market Reaction: The worsening financial situation has dampened investor confidence in Cybin, potentially leading to downward pressure on stock prices, especially as the company has yet to achieve profitability, making the market outlook more cautious.
- Leadership Changes Impact: Helus Pharma's CEO Michael Cola has stepped down, with Eric So taking over as interim CEO, creating uncertainty in the company's strategic direction, which may affect investor confidence in future growth prospects.
- Funding Initiative Launched: Helus Pharma successfully priced a $50 million public offering at $4.85 per share, providing essential funding to support operations and drive future growth amid competitive market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HELP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HELP
Wall Street analysts forecast HELP stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.890
Low
22.00
Averages
41.17
High
55.00
Current: 5.890
Low
22.00
Averages
41.17
High
55.00
About HELP
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Expands Medical Cannabis Platform with HelloMD Acquisition
- Tilray Acquires HelloMD: Tilray Brands strengthens its medical cannabis business by acquiring HelloMD, aiming to enhance patient access and education through a digital platform, which is expected to bolster its competitive position in the global medical cannabis market.
- Vireo Expands into Pennsylvania: Vireo Growth signs an agreement with Hive Holdings to acquire a retail license for approximately $20 million, allowing the establishment of up to six medical cannabis dispensaries in Pennsylvania, further expanding its footprint in the U.S. market.
- Optimi Health Export: Optimi Health completes its third commercial shipment of 1,000 capsules of 5mg psilocybin to Australia, reflecting growing demand for psychedelic treatments for treatment-resistant depression in the country.
- Helus Pharma Financials: Helus Pharma reports a fiscal year 2026 loss of $4.25 per share, widening from the previous year, yet its lead candidate HLP003 is progressing towards a pivotal Phase 3 trial, indicating ongoing investment potential in the biotech sector.
See More
Rapid Growth in Major Depressive Disorder Treatment Market
- Market Growth Potential: The global Major Depressive Disorder treatment market is projected to grow from approximately $20 billion in 2026 to nearly $36 billion by 2033, reflecting strong long-term demand and attracting billions in investment.
- Clinical Trial Progress: Helus Pharma's HLP003 has surpassed 88% enrollment in the Phase 3 APPROACH study for MDD, with topline data expected in Q4 2026, marking a significant step towards commercialization.
- Significant Efficacy: Phase 2 data for HLP003 demonstrated a ~23-point reduction in MADRS score at 12 months after two 16mg doses, achieving a 100% response rate and 71% remission rate, indicating its potential in treating treatment-resistant depression.
- Strategic Partnerships: Helus Pharma has partnered with TARA Mind to enhance access to mental health treatment for veterans and collaborates with leading mental health organizations to support HLP003 Phase 3 recruitment, further expanding its market impact.
See More
Cybin Reports FY Net Loss of $148 Million, Up from $81.6 Million Last Year
- Deteriorating Financials: Cybin's FY report reveals a net loss of $148 million, up from $81.6 million last year, indicating increased pressure from R&D and operational costs, which may hinder future financing capabilities.
- Cautious Market Reaction: The worsening financial situation has dampened investor confidence in Cybin, potentially leading to downward pressure on stock prices, especially as the company has yet to achieve profitability, making the market outlook more cautious.
- Leadership Changes Impact: Helus Pharma's CEO Michael Cola has stepped down, with Eric So taking over as interim CEO, creating uncertainty in the company's strategic direction, which may affect investor confidence in future growth prospects.
- Funding Initiative Launched: Helus Pharma successfully priced a $50 million public offering at $4.85 per share, providing essential funding to support operations and drive future growth amid competitive market conditions.
See More
Helus Pharma's HLP003 Phase 3 Trial Enrollment Surpasses 86%
- Enrollment Milestone: Helus Pharma's HLP003 Phase 3 trial has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026, indicating the company's potential in the mental health treatment space.
- Clinical Trial Significance: Eric So noted that the continued enrollment progress underscores the execution of the clinical program, bringing them closer to the anticipated topline data release, which could provide a transformative treatment option for patients with major depressive disorder, enhancing the company's position in a competitive market.
- FDA Breakthrough Designation: HLP003 has received FDA Breakthrough Therapy Designation, aimed at expediting development and review, signaling significant improvement potential in treating major depressive disorder, thus boosting investor confidence in the program.
- Strong Market Demand: Major depressive disorder affects hundreds of millions globally, with traditional treatments offering limited relief; if HLP003 can validate its efficacy in Phase 3 trials, it could reshape the management of depression.
See More
Helus Pharma's HLP003 Phase 3 Trial Surpasses 86% Enrollment
- Significant Trial Progress: Helus Pharma's HLP003 Phase 3 trial has surpassed 86% enrollment, keeping the FDA Breakthrough Therapy program on track for a topline data readout in Q4 2026, potentially offering a new treatment option for depression.
- Clinical Data Highlights: HLP003 demonstrated substantial efficacy in Phase 2 trials, with a ~23-point reduction in MADRS scores at 12 months, and an 18-week response rate of 75%, improving to 100% at 12 months, laying a solid foundation for the upcoming Phase 3 trial.
- Strong Market Demand: With millions affected by major depressive disorder and existing treatments often inadequate, HLP003's fast-acting, neuroplasticity-oriented approach could reshape depression management, addressing the urgent need for novel therapies in the market.
- Far-reaching Strategic Implications: The Breakthrough Therapy designation accelerates HLP003's development, positioning Helus Pharma to carve out a niche in a competitive landscape, and successful Phase 3 data could pave the way for future commercialization efforts.
See More
Bio-Techne Soars Over 20% on Merck Acquisition News
- Acquisition News Boosts Stock: Bio-Techne Corp. (TECH) shares surged over 20% following the announcement of its acquisition by Merck KGaA for $73 per share, representing a total enterprise value of approximately $11.3 billion, which is a 36% premium to its one-month volume weighted average price, indicating strong market confidence in the deal.
- Strong Financial Performance: Bio-Techne generated over $1.2 billion in net sales for fiscal year 2025, and the acquisition is expected to immediately enhance Merck KGaA's profitability, improving both its Life Science business and overall EBITDA pre-margin, showcasing the strategic value of the acquisition.
- Cost Savings Expectations: Merck KGaA anticipates achieving approximately €140 million in annual cost savings by the third year post-transaction, indicating significant operational efficiency gains that will further bolster the company's financial health.
- Transaction Timeline: The deal is expected to close by late 2026 or early 2027, marking a significant integration for Bio-Techne in the biotech sector, which may influence future market competitive dynamics.
See More
Tilray Expands Medical Cannabis Platform with HelloMD Acquisition
- Tilray Acquires HelloMD: Tilray Brands strengthens its medical cannabis business by acquiring HelloMD, aiming to enhance patient access and education through a digital platform, which is expected to bolster its competitive position in the global medical cannabis market.
- Vireo Expands into Pennsylvania: Vireo Growth signs an agreement with Hive Holdings to acquire a retail license for approximately $20 million, allowing the establishment of up to six medical cannabis dispensaries in Pennsylvania, further expanding its footprint in the U.S. market.
- Optimi Health Export: Optimi Health completes its third commercial shipment of 1,000 capsules of 5mg psilocybin to Australia, reflecting growing demand for psychedelic treatments for treatment-resistant depression in the country.
- Helus Pharma Financials: Helus Pharma reports a fiscal year 2026 loss of $4.25 per share, widening from the previous year, yet its lead candidate HLP003 is progressing towards a pivotal Phase 3 trial, indicating ongoing investment potential in the biotech sector.
See More
Rapid Growth in Major Depressive Disorder Treatment Market
- Market Growth Potential: The global Major Depressive Disorder treatment market is projected to grow from approximately $20 billion in 2026 to nearly $36 billion by 2033, reflecting strong long-term demand and attracting billions in investment.
- Clinical Trial Progress: Helus Pharma's HLP003 has surpassed 88% enrollment in the Phase 3 APPROACH study for MDD, with topline data expected in Q4 2026, marking a significant step towards commercialization.
- Significant Efficacy: Phase 2 data for HLP003 demonstrated a ~23-point reduction in MADRS score at 12 months after two 16mg doses, achieving a 100% response rate and 71% remission rate, indicating its potential in treating treatment-resistant depression.
- Strategic Partnerships: Helus Pharma has partnered with TARA Mind to enhance access to mental health treatment for veterans and collaborates with leading mental health organizations to support HLP003 Phase 3 recruitment, further expanding its market impact.
See More
Cybin Reports FY Net Loss of $148 Million, Up from $81.6 Million Last Year
- Deteriorating Financials: Cybin's FY report reveals a net loss of $148 million, up from $81.6 million last year, indicating increased pressure from R&D and operational costs, which may hinder future financing capabilities.
- Cautious Market Reaction: The worsening financial situation has dampened investor confidence in Cybin, potentially leading to downward pressure on stock prices, especially as the company has yet to achieve profitability, making the market outlook more cautious.
- Leadership Changes Impact: Helus Pharma's CEO Michael Cola has stepped down, with Eric So taking over as interim CEO, creating uncertainty in the company's strategic direction, which may affect investor confidence in future growth prospects.
- Funding Initiative Launched: Helus Pharma successfully priced a $50 million public offering at $4.85 per share, providing essential funding to support operations and drive future growth amid competitive market conditions.
See More
Helus Pharma's HLP003 Phase 3 Trial Enrollment Surpasses 86%
- Enrollment Milestone: Helus Pharma's HLP003 Phase 3 trial has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026, indicating the company's potential in the mental health treatment space.
- Clinical Trial Significance: Eric So noted that the continued enrollment progress underscores the execution of the clinical program, bringing them closer to the anticipated topline data release, which could provide a transformative treatment option for patients with major depressive disorder, enhancing the company's position in a competitive market.
- FDA Breakthrough Designation: HLP003 has received FDA Breakthrough Therapy Designation, aimed at expediting development and review, signaling significant improvement potential in treating major depressive disorder, thus boosting investor confidence in the program.
- Strong Market Demand: Major depressive disorder affects hundreds of millions globally, with traditional treatments offering limited relief; if HLP003 can validate its efficacy in Phase 3 trials, it could reshape the management of depression.
See More
Helus Pharma's HLP003 Phase 3 Trial Surpasses 86% Enrollment
- Significant Trial Progress: Helus Pharma's HLP003 Phase 3 trial has surpassed 86% enrollment, keeping the FDA Breakthrough Therapy program on track for a topline data readout in Q4 2026, potentially offering a new treatment option for depression.
- Clinical Data Highlights: HLP003 demonstrated substantial efficacy in Phase 2 trials, with a ~23-point reduction in MADRS scores at 12 months, and an 18-week response rate of 75%, improving to 100% at 12 months, laying a solid foundation for the upcoming Phase 3 trial.
- Strong Market Demand: With millions affected by major depressive disorder and existing treatments often inadequate, HLP003's fast-acting, neuroplasticity-oriented approach could reshape depression management, addressing the urgent need for novel therapies in the market.
- Far-reaching Strategic Implications: The Breakthrough Therapy designation accelerates HLP003's development, positioning Helus Pharma to carve out a niche in a competitive landscape, and successful Phase 3 data could pave the way for future commercialization efforts.
See More
Bio-Techne Soars Over 20% on Merck Acquisition News
- Acquisition News Boosts Stock: Bio-Techne Corp. (TECH) shares surged over 20% following the announcement of its acquisition by Merck KGaA for $73 per share, representing a total enterprise value of approximately $11.3 billion, which is a 36% premium to its one-month volume weighted average price, indicating strong market confidence in the deal.
- Strong Financial Performance: Bio-Techne generated over $1.2 billion in net sales for fiscal year 2025, and the acquisition is expected to immediately enhance Merck KGaA's profitability, improving both its Life Science business and overall EBITDA pre-margin, showcasing the strategic value of the acquisition.
- Cost Savings Expectations: Merck KGaA anticipates achieving approximately €140 million in annual cost savings by the third year post-transaction, indicating significant operational efficiency gains that will further bolster the company's financial health.
- Transaction Timeline: The deal is expected to close by late 2026 or early 2027, marking a significant integration for Bio-Techne in the biotech sector, which may influence future market competitive dynamics.
See More
